Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Ronald Drescher

Physician Assistant Clinton, UT Physician Assistant

NPI 1942306956 CMS profile 11148271

1477 North 2000 West, Westside Medical, Clinton, UT 84015

Open in the dashboard

General payments

$6,748

424 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ronald Drescher of Clinton, UT is reported in the CMS Open Payments database as having received $6,748 across 424 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,209 77
2024 General $1,319 72
2023 General $1,186 77
2022 General $1,318 86
2021 General $1,716 112

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ronald Drescher
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Ronald Drescher were reported at $1,209. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Ronald Drescher Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,716 $132 $37–$438 $132
2022 $1,318 $155 $48–$522 $149
2023 $1,186 $167 $52–$557 $160
2024 $1,319 $178 $55–$600 $164
2025 $1,209 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,280 93 payments
  2. GlaxoSmithKline, LLC. $604 45 payments
  3. Astellas Pharma US Inc $449 17 payments
  4. Lilly USA, LLC $441 35 payments
  5. AstraZeneca Pharmaceuticals LP $359 22 payments
  6. Pfizer Inc. $334 17 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $312 15 payments
  8. Abbott Laboratories $305 15 payments
  9. Janssen Pharmaceuticals, Inc $223 17 payments
  10. Amgen Inc. $199 13 payments
  11. Other $2,241 135 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $6,548 422 payments
  2. Education $200 2 payments
Products named General payments · program years 2021–2025
  1. VRAYLAR $627 46 payments
  2. SHINGRIX $315 21 payments
  3. NURTEC ODT $279 13 payments
  4. BREZTRI $276 16 payments
  5. UBRELVY $272 18 payments
  6. ZAVZPRET $242 11 payments
  7. QULIPTA $233 15 payments
  8. MOUNJARO $228 17 payments
  9. TRELEGY ELLIPTA $227 19 payments
  10. XARELTO $223 17 payments
  11. Other $5,758 359 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 131 drugs

Part D claims

5,274

Median for Physician Assistant: 241

Drug cost

$375,298

Median for Physician Assistant: $4,110

Branded share of claims

26.8%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 63 $43,583
Ozempic Semaglutide Brand 38 $39,882
Mounjaro Tirzepatide Brand 32 $33,519
Eliquis Apixaban Brand 27 $25,773
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 34 $24,072
Rexulti Brexpiprazole Brand 13 $22,202
Trulicity Dulaglutide Brand 18 $17,238
Myrbetriq Mirabegron Brand 25 $16,364
Farxiga Dapagliflozin Propanediol Brand 21 $14,393
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 21 $13,327

The 10 drugs with the highest cost, of 131 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 133 billing codes

Paid by Medicare

$65,548

Of which drugs: $15,259

Medicare patients

159

Average age 72

Services billed

5,375

94 women, 65 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Arthritis 44%
Depression 40%
Chronic kidney disease 36%
Diabetes 34%
Ischemic heart disease 21%
Heart failure 16%
Atrial fibrillation 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 11 11 $3,213
Sarscv2 vac 30mcg trs-suc im 91320 Office 16 16 $2,420
Influenza vaccine, trivalent derived from recombinant dna 90673 Office 22 22 $1,716
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 15 56 $43

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 33 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FANAPT
  • Vanda Pharmaceuticals Inc. $146
$146 — —
Veozah
  • Astellas Pharma US Inc $97
$97 — —
VRAYLAR
  • AbbVie, Inc. $92
$92 — —
Wegovy
  • Novo Nordisk Inc $77
$77 — —
JORNAY PM
  • Ironshore Pharmaceuticals Inc. $63
$63 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 33 with Patron

Records

424 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Utah

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record